Vimarsana
Biggest News Aggregation in the World

Page 11 - Managed Care News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Managed Care. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Managed Care Today - Breaking & Trending Today

OIG Sparks Public Excitement about Managed Care and Alludes to Incoming Enforcement Guidance | Sheppard Mullin Richter & Hampton LLP - Vimarsana News

OIG Sparks Public Excitement about Managed Care and Alludes to Incoming Enforcement Guidance | Sheppard Mullin Richter & Hampton LLP

“The American people deserve to know that the insurance companies receiving more than $700B annually in taxpayer funds are working to ensure you receive effective, high-quality care....

Sharecare, Inc. (NASDAQ:SHCR) Q4 2023 Earnings Call Transcript - Vimarsana News

Sharecare, Inc. (NASDAQ:SHCR) Q4 2023 Earnings Call Transcript

Sharecare, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.0195.

The Evolution of Transgender Health Care - Vimarsana News

The Evolution of Transgender Health Care

Part 1 of a 3-part, monthly feature series on the history, evolution, and current state of LGBTQ+ health care is focused on the unique needs and journey of transgender patients in the US health system, as well as the policies and social influences that have shaped their access to care.

Source: ajmc.com
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies - Vimarsana News

Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies

Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.

Source: ajmc.com
Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect - Vimarsana News

Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.

Source: ajmc.com